The Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group reported the 24-month efficacy results from 2 randomized, placebo-controlled, clinical trials of ocular photodynamic therapy with verteporfin (Visudyne; Novartis AG, Basel, Switzerland) for subfoveal choroidal neovascularization (CNV) caused by age-related macular degeneration.1 Report No. 2 from the TAP Study Group noted a visual acuity benefit at 24 months for all patients receiving verteporfin therapy in the clinical trial, and it was found to be strongest for subfoveal lesions that were predominantly classic (the area of classic CNV was at least 50% of the area of the entire lesion). In TAP Report No. 5, the 36-month vision and safety results of an open-label extension of the TAP investigation showed that the visual outcomes for patients treated with verteporfin with predominantly classic lesions at baseline remained stable from month 24 through month 36, and no additional safety concerns were identified.2 The purpose of this letter is to provide the 48-month follow-up information on patients treated long-term with verteporfin with predominantly classic CNV so that physicians may incorporate this information in treatment-management decisions.
Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Verteporfin Therapy for Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration: Four-Year Results of an Open-Label Extension of 2 Randomized Clinical Trials: TAP Report No. 7. Arch Ophthalmol. 2005;123(9):1283-1285. doi:10.1001/archopht.123.9.1283